While anti-VEGF antibodies have exhibited significant efficacy in addressing ocular hemorrhage and macular edema over the past two decades, it is noteworthy that suboptimal visual outcomes persist in a subset of patients despite these treatments. Here, VEGFA is linked to macular retinal edema.